TransCelerate BioPharma has announced the addition of two new members, Merck & Co and Novo Nordisk, to the biopharmaceutical non-profit organization. TransCelerate is comprised of influential biopharmaceutical companies that are collaborating to help accelerate and enhance the research and development of innovative drugs across therapeutic areas.

"The additions of Merck & Co. and Novo Nordisk further extend the reach of our workstream solutions that each aim to drive the efficient, effective and high-quality delivery of new medicines," said Mr Dalvir Gill, CEO, TransCelerate.

In addition, TransCelerate has appointed Mr Briggs Morrison, executive vice president, Global Medicines Development at AstraZeneca, to the position of Chair of the Board of Directors.

Mr Briggs Morrison, said, "I am very pleased to serve as the Chair of TransCelerate's Board of Directors and look forward to continuing to advance our mission of identifying and solving common drug development challenges. The year ahead will bring forth even more resources that will further facilitate the delivery of new therapies to the public faster."